| Dokumentenart: | Artikel | ||||
|---|---|---|---|---|---|
| Titel eines Journals oder einer Zeitschrift: | Clinical Colorectal Cancer | ||||
| Verlag: | CIG MEDIA GROUP, LP | ||||
| Ort der Veröffentlichung: | DALLAS | ||||
| Band: | 21 | ||||
| Nummer des Zeitschriftenheftes oder des Kapitels: | 4 | ||||
| Seitenbereich: | S. 354-361 | ||||
| Datum: | 2022 | ||||
| Institutionen: | Medizin > Lehrstuhl für Chirurgie Medizin > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) Medizin > Lehrstuhl für Pathologie Medizin > Zentren des Universitätsklinikums Regensburg > Tumorzentrum e.V. | ||||
| Identifikationsnummer: |
| ||||
| Stichwörter / Keywords: | ADJUVANT CHEMOTHERAPY; 1ST-LINE TREATMENT; COLORECTAL-CANCER; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; RISK; 5-FU; oxaliplatin; Adjuvant chemotherapy; Cancer registry; Adverse event | ||||
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||
| Status: | Veröffentlicht | ||||
| Begutachtet: | Ja, diese Version wurde begutachtet | ||||
| An der Universität Regensburg entstanden: | Ja | ||||
| Dokumenten-ID: | 57125 |
Web of ScienceZusammenfassung
Second cancer development represents a potential long-term side effects of chemotherapeutic agents. We investigated a total of 2856 Patients with UICC-stage III/IV colon cancer and identified 223 patients who had developed a subsequent second cancer. A significantly increased risk for subsequent second cancer after adjuvant chemotherapy was not detected. Interestingly, second cancer rate was ...
Zusammenfassung
Second cancer development represents a potential long-term side effects of chemotherapeutic agents. We investigated a total of 2856 Patients with UICC-stage III/IV colon cancer and identified 223 patients who had developed a subsequent second cancer. A significantly increased risk for subsequent second cancer after adjuvant chemotherapy was not detected. Interestingly, second cancer rate was decreased in patients treated with FOLFOX compared to FUFOL. The findings may have an impact on the surveillance and long-term follow-up of cancer patients. Background: Additive chemotherapeutic treatment of UICC-stage-III / IV colon cancer with fluorouracil, leucovorin and oxaliplatin is widely accepted as current standard of treatment after R0-resection. However, as patients ' survival is increasing, long-term side effects of chemotherapeutic agents such as second cancer development are becoming increasingly important. Patients: We therefore investigated a total of 2 856 Patients with UICC-stage III / IV colon cancer, 223 of whom (7.8%) had developed a subsequent second cancer. Results: Median follow-up was 73.2 months (range 209.9 months, 95%-CI 69.8-76.9). Most frequent second cancers were prostate cancer (18.4%), colon cancer (16.1%), breast cancers (8.1%), lung cancer (8.1%), rectal cancer (4.9%) and uter ine cancer (4.9%). However, in compar ison to non-treated patients this did not represent a significantly increased risk for subsequent second cancer in patients after treatment with additive chemotherapy. Of interest, our data suggest a significantly decreased second cancer rate in patients treated with FOLFOX compared to FUFOL for additive treatment. Conclusions: Second cancer development was not increased after additive chemotherapy for colon cancer, which is a novel aspect in the ongoing discussions on reduction of adjuvant treatment to 3 months or treatment of lymph node negative patients. Novelty and Impact State-ment To our knowledge, this is the first population-based study analyzing second cancer development after additive chemotherapy in patients with UICC III-IV colon cancer. The results have an important impact on the surveillance and long-term follow-up of cancer patients.
Metadaten zuletzt geändert: 29 Feb 2024 12:48
Altmetric